Aggressive gist with gastric location – case report

Spital Sf Spiridon Iași, Clinica III Chirurgie, Al XI-lea Congres al Asociației Chirurgilor „Nicolae Anestiadi” din Republica Moldova și cea de-a XXXIII-a Reuniune a Chirurgilor din Moldova „Iacomi-Răzeșu” 27-30 septembrie 2011Rezumat: Tumorile stromale gastrointestinale (GIST) sunt definite printr-un ansamblu de argumente clinice, morfologice și imunohistologice. Prezentăm cazul unei paciente în varstă de 39 ani cu GIST localizată la nivelul fornixului gastric cu metastază hepatică, cu simptomatologie clinică nespecifică. Investigatiile paraclinice - ecografia abdominală și examenul computer tomografic (CT) - au evidențiat masele tumorale intraperitoneale fără a putea sugera diagnosticul. Examenul anatomo- patologic extemporaneu stabilește diagnosticul de tumora stromală gastrică și impune conduita chirurgicală corespunzatoare.Abstract: Gastrointestinal stromal tumors (GIST) are defined by a set of clinical, morphological and imunohistological elements. We present a patient, 39 years old, female, with GIST located in the upper part of the stomach with liver metastase, with nonspecific clinical symptoms. Paraclinical - abdominal ultrasound examination and computer tomography (CT) - have shown intraperitoneal tumor masses without suggested the diagnosis of GIST. Anatomic-pathological examination, made during the operation, diagnosed stromal tumors and gastric surgery requires proper conduct

Triple primary malignancies in a patient with breast cancer: a rare occurrence

Scop. Stadializarea loco-regională și la distanță a tumorilor maligne poate evidenția prezența neoplaziilor sincrone în același organ sau la distanță. Neoplasmele primare sincrone prezente în trei sisteme de organ diferite sunt raportate în literatură cu o incidență de 2.4% -17%. Mirajul primei leziuni poate conduce frecvent spre erori de management terapeutic. Materiale și metode. O pacientă în vârstă de 66 ani, cunoscută cu importantă patologie cardiovasculară și tiroidiană, se prezintă în IRO Iași în urma decelării la palpare a unei formațiuni tumorale mamare stângi în cadranul infero-extern. La examenul clinic, se observă la nivel cutanat în zona sânului stâng o suprafață cu contur neregulat, alcătuită din zone de hipopigmentare și hiperpigmentare. Pacienta este stadializată imagistic pentru afecțiunea mamară – neoplasm ductal invaziv cT2N1 (triplu negativ) și un nodul solid neregulat în segmentul anterior al lobului stâng pulmonar. Decizia Comisiei Multidisciplinare Oncologice este de evaluare PET-CT a nodulului pulmonar, ocazie cu care se infirmă supoziția de metastază pulmonară, dar se evidențiază hipercaptare la nivelul glandei tiroide. Se decide inițierea chimioterapiei neoadjuvante pentru afecțiunea mamară, urmată de intervenție chirurgicală, secvențială, a sânului în bloc cu afecțiunea cutanată și a glandei tiroide. Rezultate. Buletinul histopatologic final a constat în răspuns complet anatomo-patologic al neoplaziei mamare și diagnosticul de microcarcinom tiroidian papilar, respectiv melanom malign cutanat tip Clark II. Pacienta a primit radioterapie adjuvantă pentru cancerul mamar, fiind supravegheată imagistic pentru cancerul tiroidian și cel cutanat. Concluzii. Tumorile maligne sunt definite ca neoplazii primare multiple dacă apar în locuri diferite și/sau aparțin unui grup histologic diferit. Astfel, este evitată clasificarea eronată a tumorilor multiple ca determinări secundare. Cazul prezentat subliniază importanța investigațiilor paraclinice efectuate meticulos pentru stadializarea preterapeutică, detecția cancerelor sincrone având un rol semnificativ în prevenția, diagnosticul și stabilirea tratamentului pacientului, în vederea obținerii celor mai bune rezultate terapeutice.Aim of study. Loco-regional and distant staging of malignant tumors can highlight the presence of synchronous neoplasias in the same organ or at distance. Synchronous primary neoplasms present in three different organ systems are reported in the literature with an incidence of 2.4%-17%. The mirage of the first lesion can often lead to therapeutic management errors. Materials and methods. A 66-year-old female patient, known to have important cardiovascular and thyroid pathology, presented to the IRO Iasi Hospital following palpation of a left mammary tumor in the infero-external quadrant. During the clinical examination, a surface with an irregular outline, made up of an area in which both hypopigmentation and hyperpigmentation are present, is observed at the skin level in the area of the left breast. The patient is staged by imaging for the breast condition – invasive ductal neoplasia cT2N1 (triple negative) and an irregular solid nodule in the anterior segment of the left lung lobe. The decision of the Multidisciplinary Oncological Team is to evaluate the PET-CT of the lung nodule, which refutes the position of lung metastasis, but shows hyper-uptake at the level of the thyroid gland. It is decided to initiate neoadjuvant chemotherapy for the breast disease, followed by sequential surgery of the breast en bloc with the skin disease and, after 3 weeks, total thyroidectomy. Results. The final histopathological report consisted of the complete pathological response of the breast cancer and the diagnosis of papillary thyroid microcarcinoma, respectively Clark II type malignant cutaneous melanoma. The patient received adjuvant radiotherapy for breast cancer, being monitored by imaging for thyroid and skin cancer. Conclusions. Malignant tumors are defined as multiple primary neoplasms if they occur in different sites and/or belong to a different histological group. Thus, the wrong classification of multiple tumors as secondary determinations is avoided. The presented case emphasizes the importance of meticulously performed paraclinical investigations for pre-therapeutic staging, the detection of synchronous cancers having a significant role in the prevention, diagnosis and stability of the patient's treatment, in order to obtain the best therapeutic results

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named ‘Immunoscore’ has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune). © 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland

Changing outcomes following pelvic exenteration for locally advanced and recurrent rectal cancer

Background Pelvic exenteration for locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC) is technically challenging but increasingly performed in specialist centres. The aim of this study was to compare outcomes of exenteration over time. Methods This was a multicentre retrospective study of patients who underwent exenteration for LARC and LRRC between 2004 and 2015. Surgical outcomes, including rate of bone resection, flap reconstruction, margin status and transfusion rates, were examined. Outcomes between higher- and lower-volume centres were also evaluated. Results Some 2472 patients underwent pelvic exenteration for LARC and LRRC across 26 institutions. For LARC, rates of bone resection or flap reconstruction increased from 2004 to 2015, from 3.5 to 12.8 per cent, and from 12.0 to 29.4 per cent respectively. Fewer units of intraoperative blood were transfused over this interval (median 4 to 2 units; P = 0.040). Subgroup analysis showed that bone resection and flap reconstruction rates increased in lower- and higher-volume centres. R0 resection rates significantly increased in low-volume centres but not in high-volume centres over time (low-volume: from 62.5 to 80.0 per cent, P = 0.001; high-volume: from 83.5 to 88.4 per cent, P = 0.660). For LRRC, no significant trends over time were observed for bone resection or flap reconstruction rates. The median number of units of intraoperative blood transfused decreased from 5 to 2.5 units (P < 0.001). R0 resection rates did not increase in either low-volume (from 51.7 to 60.4 per cent; P = 0.610) or higher-volume (from 48.6 to 65.5 per cent; P = 0.100) centres. No significant differences in length of hospital stay, 30-day complication, reintervention or mortality rates were observed over time. Conclusion Radical resection, bone resection and flap reconstruction rates were performed more frequently over time, while transfusion requirements decreased

Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative

Pelvic exenteration is a complex operation performed for locally advanced and recurrent pelvic cancers. The goal of surgery is to achieve clear margins, therefore identifying adjacent or involved organs, bone, muscle, nerves and/or vascular structures that may need resection. While these extensive resections are potentially curative, they can be associated with substantial morbidity. Recently, there has been a move to centralize care to specialized units, as this facilitates better multi-disciplinary care input. Advancements in pelvic oncology and surgical innovation have redefined the boundaries of pelvic exenterative surgery. Combined with improved neoadjuvant therapies, advances in diagnostics, and better reconstructive techniques have provided quicker recovery and better quality of life outcomes, with improved survival This article provides highlights of the current management of advanced pelvic cancers in terms of surgical strategy and potential future developments

Perioperative management and anaesthetic considerations in pelvic exenterations using Delphi methodology: Results from the PelvEx Collaborative

Background: The multidisciplinary perioperative and anaesthetic management of patients undergoing pelvic exenteration is essential for good surgical outcomes. No clear guidelines have been established, and there is wide variation in clinical practice internationally. This consensus statement consolidates clinical experience and best practice collectively, and systematically addresses key domains in the perioperative and anaesthetic management. Methods: The modified Delphi methodology was used to achieve consensus from the PelvEx Collaborative. The process included one round of online questionnaire involving controlled feedback and structured participant response, two rounds of editing, and one round of web-based voting. It was held from December 2019 to February 2020. Consensus was defined as more than 80 per cent agreement, whereas less than 80 per cent agreement indicated low consensus. Results: The final consensus document contained 47 voted statements, across six key domains of perioperative and anaesthetic management in pelvic exenteration, comprising preoperative assessment and preparation, anaesthetic considerations, perioperative management, anticipating possible massive haemorrhage, stress response and postoperative critical care, and pain management. Consensus recommendations were developed, based on consensus agreement achieved on 34 statements. Conclusion: The perioperative and anaesthetic management of patients undergoing pelvic exenteration is best accomplished by a dedicated multidisciplinary team with relevant domain expertise in the setting of a specialized tertiary unit. This consensus statement has addressed key domains within the framework of current perioperative and anaesthetic management among patients undergoing pelvic exenteration, with an international perspective, to guide clinical practice, and has outlined areas for future clinical research

Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: Study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)

Background: A resection with clear margins (R0 resection) is the most important prognostic factor in patients with locally recurrent rectal cancer (LRRC). However, this is achieved in only 60 per cent of patients. The aim of this study is to investigate whether the addition of induction chemotherapy to neoadjuvant chemo(re)irradiation improves the R0 resection rate in LRRC. Methods: Thismulticentre, international, open-label, phase III, parallel-arms study will enrol 364 patients with resectable LRRC after previous partial or total mesorectal resection without synchronous distant metastases or recent chemo- and/or radiotherapy treatment. Patients will be randomized to receive either induction chemotherapy (three 3-week cycles of CAPOX (capecitabine, oxaliplatin), four 2- week cycles of FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or FOLFORI (5-fluorouracil, leucovorin, irinotecan)) followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm). Tumours will be restaged usingMRI and, in the experimental arm, a further cycle of CAPOX or two cycles of FOLFOX/FOLFIRI will be administered before chemoradiotherapy in case of stable or responsive disease. The radiotherapy dose will be 25 × 2.0 Gy or 28 × 1.8Gy in radiotherapy-naive patients, and 15 × 2.0Gy in previously irradiated patients. The concomitant chemotherapy agent will be capecitabine administered twice daily at a dose of 825mg/m2 on radiotherapy days. The primary endpoint of the study is the R0 resection rate. Secondary endpoints are long-termoncological outcomes, radiological and pathological response, toxicity, postoperative complications, costs, and quality of life. Discussion: This trial protocol describes the PelvEx II study. PelvEx II, designed as a multicentre, open-label, phase III, parallel-arms study, is the first randomized study to compare induction chemotherapy followed by neoadjuvant chemo(re)irradiation and surgery with neoadjuvant chemo(re)irradiation and surgery alone in patients with locally recurrent rectal cancer, with the aim of improving the number of R0 resections

Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II)

Background A resection with clear margins (R0 resection) is the most important prognostic factor in patients with locally recurrent rectal cancer (LRRC). However, this is achieved in only 60 per cent of patients. The aim of this study is to investigate whether the addition of induction chemotherapy to neoadjuvant chemo(re)irradiation improves the R0 resection rate in LRRC. Methods This multicentre, international, open-label, phase III, parallel-arms study will enrol 364 patients with resectable LRRC after previous partial or total mesorectal resection without synchronous distant metastases or recent chemo- and/or radiotherapy treatment. Patients will be randomized to receive either induction chemotherapy (three 3-week cycles of CAPOX (capecitabine, oxaliplatin), four 2-week cycles of FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) or FOLFORI (5-fluorouracil, leucovorin, irinotecan)) followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm). Tumours will be restaged using MRI and, in the experimental arm, a further cycle of CAPOX or two cycles of FOLFOX/FOLFIRI will be administered before chemoradiotherapy in case of stable or responsive disease. The radiotherapy dose will be 25 × 2.0 Gy or 28 × 1.8 Gy in radiotherapy-naive patients, and 15 × 2.0 Gy in previously irradiated patients. The concomitant chemotherapy agent will be capecitabine administered twice daily at a dose of 825 mg/m2 on radiotherapy days. The primary endpoint of the study is the R0 resection rate. Secondary endpoints are long-term oncological outcomes, radiological and pathological response, toxicity, postoperative complications, costs, and quality of life. Discussion This trial protocol describes the PelvEx II study. PelvEx II, designed as a multicentre, open-label, phase III, parallel-arms study, is the first randomized study to compare induction chemotherapy followed by neoadjuvant chemo(re)irradiation and surgery with neoadjuvant chemo(re)irradiation and surgery alone in patients with locally recurrent rectal cancer, with the aim of improving the number of R0 resections